IGC Pharma Inc. announced that it has reached a 65% patient enrollment milestone in its ongoing Phase 2 CALMA clinical trial, which is evaluating IGC-AD1 for the treatment of agitation in Alzheimer's disease. The company reported that approximately 25% of enrolled participants were recruited through targeted social media campaigns, while 75% were enrolled via direct clinical-site efforts. Interim analyses previously announced by the company have indicated clinical and statistically significant reductions in agitation. Full enrollment for the trial is targeted for early 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IGC Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1115768) on December 09, 2025, and is solely responsible for the information contained therein.